Longitudinal changes in the odds of metabolic syndrome among people living with HIV receiving dolutegravir-, tenofovir alafenamide-, or protease inhibitor-based antiretroviral therapy: a 144-week analysis from the VISEND Trial in Zambia

MetS has emerged as a growing concern among PLHIV receiving ART in Sub-Saharan Africa (SSA), and the metabolic changes may differ across ART regimens. We aimed to assess longitudinal changes in the odds of MetS across three ART regimens among PLHIV, using data from the VISEND trial over 144 weeks. We conducted a longitudinal cohort study within the VISEND trial, involving 899 adults living with HIV in Zambia. Participants were randomized to one of three ART regimens: a protease inhibitor-based arm ( n = 284), tenofovir alafenamide/emtricitabine/dolutegravir (TAFED, n = 295), or tenofovir/lamivudine/dolutegravir (TLD, n = 320). MetS was assessed using ATP III criteria over 144 weeks. We applied generalized estimating equations to assess differences in MetS odds across the three ART regimens and estimate adjusted odds ratios (ORs), with marginal predictions used to estimate regimen-specific odds. Median age was 44 years (IQR 37–50), and 61.6% were female. MetS prevalence rose over 144 weeks, peaking at week 120 (TLD: 36.6%; TAFED: 35.2%; PI-based regimens: 26.0%). In adjusted models, odds of MetS varied across regimens: TLD showed higher odds (aOR = 1.33, 95% CI: 1.05–1.78; p = 0.036), while TAFED’s association was attenuated (aOR = 1.24, 95% CI: 0.97–1.66; p = 0.127). No significant difference emerged between TAFED and TLD. Women had higher odds (aOR = 1.66, 95% CI: 1.16–2.39; p = 0.006). Older age and higher CD4 count were independently associated with higher odds of MetS. MetS increased progressively over 144 weeks across the three ART regimens. TLD was independently associated with higher odds, while TAFED was not significant after adjustment. Age and CD4 count independently associated with MetS, underscoring host factors and immune recovery. Routine metabolic screening and integrated cardiovascular odds management should accompany DTG scale-up. Trial registration: PACTR201904781300573.

Authors

Institutions

Publication Details

Journal
AIDS Research and Therapy
Published
2026-11-18
DOI
https://doi.org/10.1186/s12981-026-00988-w
Primary Topic
HIV-related health complications and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Longitudinal changes in the odds of metabolic syndrome among people living with HIV receiving dolutegravir-, tenofovir alafenamide-, or protease inhibitor-based antiretroviral therapy: a 144-week analysis from the VISEND Trial in Zambia

Sody Mweetwa Munsaka, Sombo Fwoloshi, Violet J. Kayamba, Isaac Fwemba et al.
4 links
AIDS Research and Therapy
HIV-related health complications and treatments
article

Longitudinal changes in the odds of metabolic syndrome among people living with HIV receiving dolutegravir-, tenofovir alafenamide-, or protease inhibitor-based antiretroviral therapy: a 144-week analysis from the VISEND Trial in Zambia

Sody Mweetwa Munsaka, Sombo Fwoloshi, Violet J. Kayamba, Isaac Fwemba, Wilbroad Mutale, Musalula Sinkala, Lloyd Mulenga, Mpanji Siwingwa, Douglas C. Heimburger, Suilanji Sivile, Scott Hazelhurst, Danielle Engamba
article en

Abstract

MetS has emerged as a growing concern among PLHIV receiving ART in Sub-Saharan Africa (SSA), and the metabolic changes may differ across ART regimens. We aimed to assess longitudinal changes in the odds of MetS across three ART regimens among PLHIV, using data from the VISEND trial over 144 weeks. We conducted a longitudinal cohort study within the VISEND trial, involving 899 adults living with HIV in Zambia. Participants were randomized to one of three ART regimens: a protease inhibitor-based arm ( n = 284), tenofovir alafenamide/emtricitabine/dolutegravir (TAFED, n = 295), or tenofovir/lamivudine/dolutegravir (TLD, n = 320). MetS was assessed using ATP III criteria over 144 weeks. We applied generalized estimating equations to assess differences in MetS odds across the three ART regimens and estimate adjusted odds ratios (ORs), with marginal predictions used to estimate regimen-specific odds. Median age was 44 years (IQR 37–50), and 61.6% were female. MetS prevalence rose over 144 weeks, peaking at week 120 (TLD: 36.6%; TAFED: 35.2%; PI-based regimens: 26.0%). In adjusted models, odds of MetS varied across regimens: TLD showed higher odds (aOR = 1.33, 95% CI: 1.05–1.78; p = 0.036), while TAFED’s association was attenuated (aOR = 1.24, 95% CI: 0.97–1.66; p = 0.127). No significant difference emerged between TAFED and TLD. Women had higher odds (aOR = 1.66, 95% CI: 1.16–2.39; p = 0.006). Older age and higher CD4 count were independently associated with higher odds of MetS. MetS increased progressively over 144 weeks across the three ART regimens. TLD was independently associated with higher odds, while TAFED was not significant after adjustment. Age and CD4 count independently associated with MetS, underscoring host factors and immune recovery. Routine metabolic screening and integrated cardiovascular odds management should accompany DTG scale-up. Trial registration: PACTR201904781300573.

AIDS Research and Therapy
University of Cape Town (ZA), University of the Witwatersrand (ZA), University Teaching Hospital (ZM), Lusaka Apex Medical University (ZM), University of Zambia (ZM), Levy Mwanawasa Medical University (ZM), Institute of Infectious Disease and Molecular Medicine (ZA), Vanderbilt University Medical Center (US)
Good health and well-being
HIV-related health complications and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon